
Roche Holding AG
RHHBF
Updated: 23/09/2026, 13:58:08
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).
No summaries found.
- Share price
- $453.84
- Market cap
- $361.60B
- Exchange
- OTC
- Currency
- USD
- CEO
- Thomas Schinecker
- Employees
- 103,249
- IPO date
- 03/08/2012
- Beta
- 0.347
- Last dividend
- $0.00
- Day range
- $433.00 – $453.84
- 52-week range
- $301.27 – $514.08
- 1-day performance
- 2.00%
- 1-year performance
- 50.64%
- Current drawdown (1Y)
- -11.72%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- CH0012032113
- Created
- 07/12/2025, 13:58:52
- Last update
- 23/09/2026, 13:58:08
Track Roche Holding AG with an AI analyst
See which prediction-market events move RHHBF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.